Table 1.

Primary data extracted from the included studies for meta-analysis.

Author	Year	Country	Study type	Sample method	Blinding method	Number of lesions	Male/female	Age, year (mean or range)	Mean size of tumors, mm	Site of lesions
Bhatia et al. (27)	2010	China	NR	Consecutive	Single blind	65	48/13	60.5	26	Parotid (57) and submandibular (8)
Dumitriu et al. (28)	2011	Romania	NR	Consecutive	Single blind	74	37/29	50.8	29.54	Parotid (63) and submandibular (11)
Klintworth et al. (18)	2012	Germany	R	NR	Single blind	57	27/30	53.3	NR	Parotid
Yerli et al. (29)	2012	Turkey	P	Consecutive	Single blind	36	NR	NR	19.5	Parotid (30) and submandibular (6)
Celebi et al. (30)	2012	Turkey	P	Consecutive	Single blind	81	36/39	Men: 44.75; women: 49.44	NR	Parotid
Badea et al. (19)	2013	Romania	P	NR	NR	20	15/5	40-72	NR	Parotid
Wierzbicka et al. (21)	2013	Poland	P	Consecutive	NR	43	16/27	54	NR	Parotid
Yu et al. (31)	2016	China	NR	NR	Double blind	51	NR	45	NR	Parotid
Zhou et al. (32)	2016	China	R	Consecutive	Single blind	40	26/14	44	24.9	Parotid (29) and submandibular (11)
Cortcu et al. (33)	2017	Turkey	P	Consecutive	Single blind	39	22/17	52	PA: 27.8; WT: 33; other benign: 28; malignant: 25.6	parotid
Mansour et al. (20)	2017	Germany	P	NR	NR	202	NR	58.6	NR	Parotid
Cantisani et al. (34)	2017	Italy	P	Consecutive	Single blind	63	36/29	56	NR	Parotid
Altinbas et al. (35)	2017	Turkey	P	Consecutive	NR	54	26/20	60.01	23.68	Parotid
Liu et al. (36)	2018	China	P	Consecutive	Single blind	76	40/36	47.24	Benign: 24.53; malignant: 25.05	Parotid
Karaman et al. (37)	2019	Turkey	P	NR	Single blind	60	30/30	48.8	24.36	Parotid (42) and submandibular (18)
Matsuda et al. (38)	2020	Japan	R	Consecutive	Single blind	185	103/65	Benign: 62.8; malignant: 62.7	Benign: 27.6; malignant: 31.5	Parotid (169), submandibular (15), and sublingual (1)

NR, not reported; P, prospective; R, retrospective; PA, pleomorphic adenocarcinoma; WT, Warthin tumor.